葛兰素史克制药宣布战略转型，在美国直接商业化和分销RYALTRIS®，大幅扩展其创新产品组合

发布时间：2026-04-01来源：PR Newswire

RYALTRIS

is Glenmark's first innovative product introduced

格伦马克推出的第一款创新产品

into the U.S. market

进入美国市场

ELMWOOD PARK, N.J.

新泽西州埃尔姆伍德帕克

，

April 1, 2026

2026年4月1日

/PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS

/PRNewswire/ -- 格伦马克制药公司美国分公司（Glenmark）今天宣布，将负责RYALTRIS的端到端商业化和分销。

(Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray in the United States, effective April 1, 2026.

（盐酸奥洛他定和糠酸莫米松）鼻喷雾剂，每喷665微克/25微克*，在美国，自2026年4月1日起生效。

This marks a meaningful step in Glenmark's continued expansion in the region with a sustainable approach to building a strong, direct commercial U.S. based presence.

这标志着格伦马克公司在该地区持续扩张的一个重要步骤，并以可持续的方式建立强大的、直接的美国商业存在。

RYALTRIS

丽雅卓斯

was launched in the United States in 2022 and is approved by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of symptoms associated with Seasonal Allergic Rhinitis (SAR) in adults and paediatric patients 12 years of age and older

于2022年在美国上市，并获美国食品药物监督管理局（U.S. FDA）批准用于治疗12岁及以上成人和儿童患者的季节性过敏性鼻炎（SAR）相关症状。

. It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. The product is supplied as a 240-metered spray nasal suspension.

这是一种固定剂量组合的鼻喷雾剂，将盐酸奥洛他定（一种抗组胺药）和糠酸莫米松（一种皮质类固醇）结合在单一配方中。该产品为240计量喷雾鼻悬液。

Seasonal Allergic Rhinitis affects millions of patients across the United States and remains an area where symptom control and treatment adherence continue to be important considerations. By combining two established therapies in one formulation, RYALTRIS

季节性过敏性鼻炎影响着美国数百万患者，症状控制和治疗依从性仍然是需要重点考虑的方面。通过将两种成熟的疗法结合在一种配方中，RYALTRIS

offers a convenient treatment option

提供了便捷的治疗选择

aligned with evolving patient and physician preferences.

与不断变化的患者和医生偏好保持一致。

Glenmark will directly lead brand strategy, market access, and customer engagement for RYALTRIS

Glenmark 将直接领导 RYALTRIS 的品牌战略、市场准入和客户互动。

in the U.S. This allows for more focused execution, closer alignment with healthcare providers and greater responsiveness to market needs.

在美国，这使得执行更加集中，与医疗保健提供者的更紧密合作以及对市场需求的更大响应成为可能。

Commenting on the development, Marc Kikuchi, President & Business Head, North America

就此发展发表评论的北美区总裁兼业务主管马克·木村

said, 'The commercialization by Glenmark for RYALTRIS

表示，“Glenmark 对 RYALTRIS 的商业化

in the United States is an important step forward for the growth of our company. It allows us greater operational direction in how we engage the market and support healthcare providers and patients across the nation. Today's announcement also marks a significant moment in our broader effort to strengthen our innovative businesses in the U.S.

在美国是公司发展迈出的重要一步。它让我们在如何开拓市场、如何支持全国的医疗保健供应商和患者方面拥有更大的操作空间。今天的声明也标志着我们加强美国创新业务的更广泛努力中的重要时刻。

and build a more direct, sustainable commercial presence over time.'.

并随着时间的推移建立更直接、更可持续的商业存在。

RYALTRIS

is already approved in key markets including the United States, European Union, United Kingdom, Australia, South Korea, Russia and China. In FY26, RYALTRIS

已在包括美国、欧盟、英国、澳大利亚、韩国、俄罗斯和中国在内的主要市场获得批准。在26财年，RYALTRIS

was launched in 11 additional markets, expanding its presence to 55 countries worldwide.

在另外11个市场推出，将其覆盖范围扩展到全球55个国家。

*Calculated on the anhydrous basis

*按无水物计算

RYALTRIS

Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland.

鼻喷雾剂批准的处方信息，格伦马克专科公司，瑞士。

Please click

请点击

here

这里

to view full prescribing information, including Important Safety Information.

查看完整的处方信息，包括重要的安全信息。

For additional information about RYALTRIS

有关RYALTRIS的更多信息

and how to access, please visit

以及如何访问，请访问

us.ryaltris.com

。

RYALTRIS is a registered trademark of Glenmark Specialty SA.

RYALTRIS 是 Glenmark Specialty SA 的注册商标。

About Glenmark Pharmaceuticals Limited

关于格伦马克制药有限公司

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world.

格伦马克制药有限公司（BSE：532296）（NSE：GLENMARK）是一家全球性的、以研究为主导的制药公司，专注于创新和可及性。我们开创了旨在重新定义治疗的变革性突破疗法，同时为世界各地的患者提供高质量且价格合理的药物。

With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology.

我们在四大洲拥有11家世界级制造工厂，由6个尖端研发中心提供支持，并在80多个国家拥有商业版图，专注于呼吸系统、皮肤病学和肿瘤学领域，提供涵盖品牌药、创新药、仿制药和消费健康产品的多元化产品组合。

Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit .

Scrip 100榜单根据2024年药品销售额将格伦马克列为全球前100家生物制药公司之一。欲了解更多信息，请访问。

www.glenmarkpharma.com

。

Logo:

标志：

https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg

SOURCE Glenmark Pharmaceuticals

来源：格伦马克制药公司

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示

转载说明：本文系转载内容，版权归原作者及原出处所有。转载目的在于传递更多行业信息，文章观点仅代表原作者本人，与本平台立场无关。若涉及作品版权问题，请原作者或相关权利人及时与本平台联系，我们将在第一时间核实后移除相关内容。